The study of Pharmacoeconomics analysis on anti tuberculosis drugs Rifampicin & Ethambutol

  • Arsalan Sarmad Department of Pharmacology, Global college of Pharmacy, Moinabad, Hyderabad, India.
  • B. Syed Salman Department of Pharmaceutics, Global college of Pharmacy, Moinabad, Hyderabad, India.
  • Syed Sharfuddin Ibrahim Department of Pharmacology, Global college of Pharmacy, Moinabad, Hyderabad, India.
Keywords: Pharmacoeconomics, TB drugs, Anti-tuberculosis, clinical pharmacy, COI, CBA

Abstract

Cost-benefit analysis can be used to quantify the value of clinical pharmacy services. Providing Effective Therapy and Minimum cost, Quantify costs of care, Quantify outcomes, Assess whether and by how much average costs and outcomes differ among treatment groups, Compare magnitude of difference in costs and outcomes and evaluate “value for costs” by reporting a cost-effectiveness ratio, net monetary benefit, or probability that ratio is acceptable – Potential hypothesis: Cost per quality-adjusted life year saved significantly less than Rs.75,000, To Perform sensitivity analysis. For providing good effective therapy with less adverse drug reaction at affordable price, Cost-Identification, Cost-Effectiveness Analysis, Cost-Utility Analysis, Cost-Benefit Analysis, Clinical outcomes: Cure, comfort and survival, Humanistic outcomes: Physical, emotional, social function, role performance, Economic outcomes, Economic Evaluation, Cost of Illness Evaluation (COI), Cost Benefit Analysis (CBA), Cost Minimization Analysis, Cost Effective Analysis: Cost Utility Analysis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Published
28-12-2018
How to Cite
Sarmad, A., Salman, B. S., & Sharfuddin Ibrahim, S. (2018). The study of Pharmacoeconomics analysis on anti tuberculosis drugs Rifampicin & Ethambutol. International Journal of Research in Hospital and Clinical Pharmacy, 1(1), 31-40. https://doi.org/10.33974/ijrhcp.v1i1.27
Section
Research Articles